GlaxoSmithKline Pharmaceuticals Limited announces results for the quarter ended June 30, 2022

Strong underlying growth with market share gains

GlaxoSmithKline Pharmaceuticals Limited today declared its financial results for the quarter ended June 30, 2022. Revenue (from continuing operations) for the quarter came in at Rs 729 crores. Profit After Tax (from continuing operations) at Rs 116 crores recorded a growth of 8%. EBITDA margins (from continuing operations) improving by 1.5%.

Commenting on the results, Sridhar Venkatesh, Managing Director, GlaxoSmithKline Pharmaceuticals Limited, said, "Our results reflect good momentum across general medicines and vaccines during the quarter. We have delivered strong underlying growth with market share gains across focus brands. Our vaccines business has maintained leadership in the self-pay segment while the overall vaccines market continues to be in decline.

During the quarter, we launched one of our innovative products, Trelegy Ellipta the first single-inhaler triple therapy (SITT) in India for Chronic Obstructive Pulmonary Disease (COPD) patients in a once-daily regime for patients aged 18 and above. With this launch, we are enabling Indian COPD patients to benefit from this world-leading medicine. We expect to build on this momentum as we continue to invest in our focus brands to drive growth."

About GlaxoSmithKline Pharmaceuticals Limited

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of GSK plc, a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. For more information, visit

Media Contact

Ransom D'Souza
Communications & Government Affairs